Soleno Therapeutics Stock Analysis

Soleno Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.79. Soleno Therapeutics last dividend was issued on the 6th of October 2017. The entity had 1:15 split on the 26th of August 2022. Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. Soleno Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. To find out more about Soleno Therapeutics contact Anish MD at 650 213 8444 or learn more at https://soleno.life.

Soleno Therapeutics Investment Alerts

Soleno Therapeutics Upcoming and Recent Events

Soleno Largest EPS Surprises

View All Earnings Estimates

Soleno Therapeutics Environmental, Social, and Governance (ESG) Scores

Soleno Stock Institutional Investors

Note, although Soleno Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Soleno Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.41 B.

Soleno Profitablity

Management Efficiency

Soleno Therapeutics has return on total asset (ROA) of (0.4805) % which means that it has lost $0.4805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9111) %, meaning that it created substantial loss on money invested by shareholders. Soleno Therapeutics' management efficiency ratios could be used to measure how well Soleno Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -0.24. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Soleno Therapeutics' Total Assets are very stable compared to the past year. As of the 2nd of December 2024, Non Current Assets Total is likely to grow to about 9.9 M, while Non Currrent Assets Other are likely to drop about 141.1 K.

Technical Drivers

As of the 2nd of December, Soleno Therapeutics has the Coefficient Of Variation of 1389.11, semi deviation of 2.5, and Risk Adjusted Performance of 0.0625. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Soleno Therapeutics, as well as the relationship between them.

Soleno Therapeutics Price Movement Analysis

Soleno Therapeutics Insider Trading Activities

Soleno Therapeutics Outstanding Bonds

Soleno Therapeutics Predictive Daily Indicators

Soleno Therapeutics Corporate Filings

Soleno Therapeutics Forecast Models

Soleno Therapeutics' time-series forecasting models are one of many Soleno Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Soleno Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Soleno Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Soleno shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Soleno Therapeutics. By using and applying Soleno Stock analysis, traders can create a robust methodology for identifying Soleno entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Soleno analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Soleno analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Soleno Therapeutics stock analysis indicators help investors evaluate how Soleno Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Soleno Therapeutics shares will generate the highest return on investment. By understating and applying Soleno Therapeutics stock analysis, traders can identify Soleno Therapeutics position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.